<DOC>
	<DOC>NCT02346942</DOC>
	<brief_summary>The Primary objective of this study is to understand the rheumatoid arthritis (RA) population in national integrated delivery network who are treated with first- or second-line biologic disease modifying anti-rheumatic drug (bDMARD) therapy (with or without Methotrexate) and to evaluate switching patterns and reasons for switching to another bDMARD.</brief_summary>
	<brief_title>Factors Associated With Biologic DMARD Switching</brief_title>
	<detailed_description />
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Diagnosis of RA (ICD9 714.xx) anytime during the study time period of 1/1/2007 to 10/31/2012 Patients â‰¥18 years of age at diagnosis date Required to have to have 6 months preindex and 12 months postindex continuous membership and drug benefit eligibility in the database Patients less than 18 years of age on diagnosis date If they had a diagnosis of Crohn's disease, psoriasis, psoriatic arthritis, ulcerative colitis, ankylosing spondylitis, regional enteritis, or anal fistula during the preindex period Patients who had &lt;7 days supply of adalimumab or etanercept Patients currently in a clinical trial during our study If patients are in the secondline cohort and have more than 1 prior bDMARD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>